Literature DB >> 8690419

Cirrhotic cardiomyopathy: getting to the heart of the matter.

Z Ma1, S S Lee.   

Abstract

In cirrhosis, cardiac contractile function has been extensively documented to be abnormal. At baseline, cardiac output is increased, and this is one of the characteristics of hyperdynamic circulation. However, when cirrhotic patients are challenged by pharmacological or physiological stress, ventricular hyporesponsiveness is revealed. Similar patterns have been noted in cirrhotic animal models. This phenomenon has been termed "cirrhotic cardiomyopathy." Although alcohol abuse may contribute to some cases of cirrhotic cardiomyopathy, it has been clearly documented to occur even in the absence of alcohol ingestion. Diminished myocardial beta-adrenergic receptor signal transduction function, possibly caused by a persistent elevation in norepinephrine content, has been shown to play an important role. Alternation in cardiac plasma membrane properties due to impaired lipid metabolism is also crucial. Other possible pathogenic factors are reviewed, including accumulation of cardiodepressant substances caused by hepatocellular insufficiency, and ventricular overload secondary to increased blood volume and hyperdynamic circulation. Because the cardiac reserve function is borderline in patients with cirrhosis, cardiovascular status should be carefully monitored, especially when patients undergo stresses such as liver transplantation or portosystemic shunting procedures.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690419     DOI: 10.1002/hep.510240226

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  53 in total

1.  Cardiac changes in pediatric liver transplant recipients: are they truly irreversible?

Authors:  Florence Wong
Journal:  Hepatol Int       Date:  2016-02-16       Impact factor: 6.047

Review 2.  Does cirrhotic cardiomyopathy exist? 50 years of uncertainty.

Authors:  Pierpaolo Pellicori; Concetta Torromeo; Angela Calicchia; Alessandra Ruffa; Martina Di Iorio; John G F Cleland; Manuela Merli
Journal:  Clin Res Cardiol       Date:  2013-09-01       Impact factor: 5.460

3.  Cirrhotic cardiomyopathy: an endocannabinoid connection?

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

Review 4.  Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.

Authors:  Francesco Salerno; Alexander Gerbes; Pere Ginès; Florence Wong; Vicente Arroyo
Journal:  Gut       Date:  2007-03-27       Impact factor: 23.059

Review 5.  Cardiovascular determinants of survival in cirrhosis.

Authors:  Samuel S Lee; Hongqun Liu
Journal:  Gut       Date:  2007-06       Impact factor: 23.059

6.  Origins of cardiac dysfunction in cirrhosis.

Authors:  W Jiménez; V Arroyo
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

Review 7.  Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease.

Authors:  S Møller; J H Henriksen
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

Review 8.  Cardiac evaluation of liver transplant candidates.

Authors:  Mercedes Susan Mandell; Joann Lindenfeld; Mei-Yung Tsou; Michael Zimmerman
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

9.  Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.

Authors:  J H Henriksen; J P Gøtze; S Fuglsang; E Christensen; F Bendtsen; S Møller
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

10.  Analysis of impaired exercise capacity in patients with cirrhosis.

Authors:  S K Epstein; R L Ciubotaru; M D Zilberberg; L M Kaplan; C Jacoby; R Freeman; M M Kaplan
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.